Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Lorundrostat, a highly selective aldosterone synthase inhibitor (ASI), produced similar placebo-adjusted reductions in systolic blood pressure in patients with and without 

 and lowered albuminuria by 52.2% in those with baseline albuminuria, according to a subgroup analysis of the phase 3 Launch-HTN trial.

Liffert Vogt, MD, PhD, Professor of Clinical Nephrology and Renal Physiology at Amsterdam University Medical Center and the University of Amsterdam, presented the findings at 

 in Denver, Colorado, and Mineralys Therapeutics announced the results.

“These results are encouraging. Besides impacting blood pressure in participants with and without kidney disease, treatment with lorundrostat showed a meaningful reduction in albuminuria, a key marker for cardiovascular and kidney risk control,” Vogt said in a press release.

 “In patients with chronic kidney disease, high blood pressure and albuminuria are two of the most important risk factors we can modify, and lorundrostat improved both in this trial.”

In the overall Launch-HTN population, lorundrostat 50 mg reduced automated office systolic blood pressure (AOSBP) by 9.1 mm Hg versus placebo at week 6 and 11.7 mm Hg at week 12.

 In the earlier phase 2 Explore-CKD trial, lorundrostat lowered AOSBP by 7.5 mm Hg and albuminuria by 25.6% compared with placebo in adults with CKD already receiving a renin-angiotensin system inhibitor and an SGLT2 inhibitor.

How Did Lorundrostat Affect Blood Pressure in Patients With CKD?

The analysis included 808 participants with uncontrolled hypertension receiving > 2 antihypertensive medications, randomized to once-daily lorundrostat 50 mg (n = 538) or placebo (n = 270).

 CKD was defined as an eGFR < 60 mL/min/1.73 m² or a urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g, and investigators examined AOSBP changes across CKD stages 1 to 3. The trial’s primary end point was the change in AOSBP versus placebo at week 6.

At week 12, placebo-adjusted AOSBP reduction was 9.6 mm Hg in participants with CKD (

 = .0022) and 12.2 mm Hg in those without CKD (

 <.0001).¹,² According to Mineralys, reductions in participants with CKD appeared as early as week 2 and were consistent across stages 1 to 3.

Among participants with CKD, 44% receiving lorundrostat reached systolic blood pressure < 130 mm Hg at week 12, compared with 18% receiving placebo. In participants without CKD, the corresponding rates were 48% with lorundrostat and 22% with placebo.

What Were the Albuminuria, Potassium, and eGFR Findings With Lorundrostat?

In participants with baseline albuminuria, the placebo-adjusted percent change in geometric mean UACR at week 12 was −52.2% (95% CI, −64.0% to −36.6%; 

 < .001).¹ Confirmed serum potassium above 6.0 mmol/L occurred in 3 participants (2.4%) with CKD receiving lorundrostat and in none without CKD.

Among participants receiving lorundrostat, mean cystatin C–based eGFR decreased by 7.3, 4.0, and 4.2 mL/min/1.73 m² in those with CKD stages 1, 2, and 3, respectively. This compared with a decrease of 2.1 mL/min/1.73 m² in participants without CKD. The investigators characterized the safety profile as acceptable in patients with and without CKD.

“CKD affects approximately 37 million adults in the U.S., and up to 75% of patients with CKD have uncontrolled hypertension. Aldosterone is a common driver of both hypertension and CKD, and lorundrostat is designed to reduce aldosterone at the source,” said Terry Ferguson, MD, Chief Medical Officer of Mineralys Therapeutics.

 “In Launch-HTN, lorundrostat provided similar blood pressure reductions in participants with or without CKD, and it not only did so across a broad spectrum of the disease, but it did it in a way that reduced albuminuria.”

Lorundrostat is under FDA review for the treatment of hypertension in combination with other antihypertensive agents, with a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. Mineralys described plans to continue developing the agent for related conditions, including CKD and obstructive sleep apnea.

Vogt L, Heagerty PJ, Bhaduri S. Blood pressure and albuminuria reduction with lorundrostat in CKD stages 1 to 3 in the Launch-HTN trial. Presented at: ASN Kidney Week 2026; October 21-25, 2026; Denver, CO. doi:10.1681/ASN.2026fy6zb248

Mineralys Therapeutics. Mineralys Therapeutics presents new lorundrostat data in participants with hypertension and chronic kidney disease at ASN Kidney Week 2026. GlobeNewswire. Published October 22, 2026. Accessed October 23, 2026. 

https://www.globenewswire.com/news-release/2026/10/22/3386983/0/en/mineralys-therapeutics-presents-new-lorundrostat-data-in-participants-with-hypertension-and-chronic-kidney-disease-at-asn-kidney-week-2026.html

Iapoce C. Lorundrostat significantly lowers blood pressure in key hypertension trials. HCPLive. Published March 10, 2025. Accessed October 23, 2026. 

https://www.hcplive.com/view/lorundrostat-significantly-lowers-blood-pressure-in-key-hypertension-trials

Beyond hypertension: lorundrostat’s potential to protect kidney function, with Matthew Weir, MD. HCPLive. Published November 12, 2025. Accessed October 23, 2026. 

https://www.hcplive.com/view/beyond-hypertension-lorundrostat-potential-protect-kidney-function-weir

Articles

Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Lorundrostat Lowers BP, Albuminuria in CKD With Uncontrolled Hypertension

Todd Schlesinger, MD, serves as a board-certified dermatologist, Mohs micrographic surgeon, and clinical investigator based in South Carolina.

Dermatologists have a growing set of tools for treating keratinocyte carcinoma outside the operating room. During the 

2026 Fall Clinical Dermatology Conference

 in Las Vegas, Nevada, Todd Schlesinger, MD, a Mohs surgeon and director of the Clinical Research Center of the Carolinas, spoke with 

’s team about the developments he considers most relevant to practice.

What’s New in Nonsurgical Skin Cancer Care, With Todd Schlesinger, MD

What Did the FDA Approve for Superficial Basal Cell Carcinoma (sBCC)?

 approval of aminolevulinic acid hydrochloride 10% gel (Ameluz; Biofrontera) with red light photodynamic therapy (PDT) for superficial basal cell carcinoma, the first PDT approval for any skin cancer. Schlesinger, lead author of the pivotal study, noted the protocol involves a 3-hour incubation and 2 to 4 cycles, with no anatomic site restriction on the label. In the phase 3 trial, 66% of actively treated patients achieved composite complete response at week 12 vs 5% with placebo-PDT.

He also highlighted adjuvant cemiplimab (Libtayo; Regeneron), approved in October 2025 for high-risk cutaneous squamous cell carcinoma after surgery and radiation, particularly in patients with perineural invasion, multiple nodal metastases, or deep invasion. In the 415-patient C-POST trial, it cut the risk of recurrence or death by 68% vs placebo (HR, 0.32). Cosibelimab, a PD-L1 inhibitor, and pembrolizumab round out 3 intravenous options for advanced disease.

Because actinic keratosis is chronic, Schlesinger recommends scheduled, repeated field therapy, such as PDT twice yearly. Some clinicians retreat with tirbanibulin despite its single-course labeling, and imiquimod and fluorouracil remain mainstays.

What Nonsurgical Skin Cancer Therapies Are in Development?

Schlesinger pointed to a crowded pipeline: pulsed energy devices for basal cell carcinoma, intralesional oncolytic and shuttle peptides, and an intralesional immunotherapy under study at his site. He expects nonsurgical options to expand to squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

2026 European Academy of Dermatology and Venereology Congress

 presentation, he said refined isolation techniques are producing purer exosome preparations with better-defined contents, and some companies have filed investigational new drug applications for indications such as hair loss. No exosome therapy is approved in the US, and current use is mostly as a cosmetic topical adjunct, but he anticipates clearer FDA and EMA pathways ahead.

Editor’s Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Schlesinger reported no relevant financial disclosures.

Smith T. Ameluz treatment becomes first FDA-approved PDT for skin cancer. HCPLive. Published September 14, 2026. Accessed October 23, 2026. 

https://www.hcplive.com/view/ameluz-treatment-becomes-first-fda-approved-pdt-skin-cancer

US Food and Drug Administration. FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma. Published October 8, 2025. Accessed October 23, 2026. 

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-adjuvant-treatment-cutaneous-squamous-cell-carcinoma

Videos

Todd Schlesinger, MD, reviews new photodynamic and adjuvant immunotherapy options for keratinocyte carcinoma, plus pipeline therapies and exosome research.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Ashkan Shoamanesh, MD | Image Credit: Academic CME

 after intracranial hemorrhage (ICrH), and even increased bleeding in this population, according to data from the ENRICH-AF trial.

 in Seoul, South Korea, by Ashkan Shoamanesh, MD, associate professor of medicine and the Marta and Owen Boris Chair in Stroke Research and Care at McMaster University. ENRICH-AF was described as the “ultimate safety test” of anticoagulation for AF patients upon its initiation.

“Direct oral anticoagulation reduces the risk of ischemic stroke in ICrH survivors with AF and might increase the risk of recurrent ICrH, but the net clinical benefit remains uncertain,” Shoamanesh and colleagues wrote. “We hypothesized that factor Xa inhibition with edoxaban would provide net benefit by reducing stroke (ischemic or hemorrhagic) or systemic embolism (SE) compared with avoiding anticoagulation in ICrH survivors with high-risk AF.”

ENRICH-AF was a prospective, randomized open-label, blinded end-point, investigator-initiated study aiming to define the efficacy and safety of edoxaban versus non-anticoagulant medical therapy in high-risk patients with AF and previous ICrH. Patients were eligible for inclusion if they were ≥45 years of age with a previous ICrH, documented AF, and a CHA2DS2-VASc score ≥2. Patients with an ICrH within 14 days, secondary macrovascular, neoplastic, or infectious causes of ICrH, and a need for ongoing oral anticoagulant therapy for indications other than AF, among other criteria, were excluded.

Patients were enrolled in a 1:1 ratio to receive either edoxaban 30 or 60 mg or non-anticoagulant medical therapy, the latter of which was determined by the local investigator and included either no antithrombotic therapy or antiplatelet monotherapy. The primary outcomes were incidence of stroke or systemic embolism from randomization to the common study end date – for an average of 3 years – and major hemorrhage as defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria. Secondary endpoints included ischemic stroke, cardiovascular death, and hemorrhagic stroke, among others.

A total of 948 patients were enrolled in the trial, with a mean age of 77 years. Over an average 28-month follow-up, Shoamanesh and colleagues recorded no significant reduction in the primary composite endpoint with edoxaban versus no anticoagulation (11.8% vs. 12.8%; HR, 0.88; 95% CI, 0.61-1.26; 

 = .48). Additionally, the primary safety outcome of ISTH major bleeding occurred in 11.6% of patients receiving edoxaban versus 5.2% receiving no anticoagulation (HR, 2.23; 95% CI, 1.39-3.59; 

“Our findings do not support the use of edoxaban in unselected patients with AF after intracranial hemorrhage, but highlight the need for an individualized decision-making approach,” Shoamanesh stated in an earlier interview. “Ongoing trials, including the double-blinded, randomized ASPIRE trial comparing apixaban vs. aspirin, will add to the evidence base. Additionally, a prospective, individual participant data meta-analysis of all trials (COCROACH) will ultimately provide useful additional insights on how best to individualize optimal stroke prevention in this very vulnerable patient population.”

Shoamanesh A. Edoxaban for Stroke Prevention in Intracranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF): An Open-Label, Blinded-Endpoint, Parallel Group Randomized Trial. Presented at the World Stroke Congress (WSC) 2026, Seoul, South Korea. October 21-23, 2026.

Population Health Research Institute. EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) (ENRICH-AF). ClinicalTrials.gov Identifier: NCT03950076. Updated September 1, 2026. Accessed October 23, 2026. 

https://clinicaltrials.gov/study/NCT03950076?term=NCT03950076&rank=1

Brooks A. ENRICH-AF: A Dosing Clue Emerges After Edoxaban's Miss, With Ashkan Shoamanesh, MD. 

https://www.hcplive.com/view/enrich-af-a-dosing-clue-emerges-after-edoxaban-s-miss-with-ashkan-shoamanesh-md

European Society of Cardiology. Safer stroke prevention strategies are needed for patients with atrial fibrillation after intracranial haemorrhage. Published August 29, 2026. Accessed October 23, 2026. 

https://www.escardio.org/news/press/press-releases/safer-stroke-prevention-strategies-are-needed-for-patients-with-atrial-fibrillation-after-intracranial-haemorrhage/

The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Arrhythmia

Edoxaban Fails to Improve Stroke Risk, Increases Bleeding Risk After Intracranial Hemorrhage

Amit X. Garg, MD, PhD, is a professor of medicine, epidemiology and biostatistics at Western University, nephrologist at London Health Sciences Centre.

Small for gestational age births and shared donor-recipient genetics complicate the picture of pregnancy after

Investigators behind a new Canadian study of pregnancy after living kidney donation are weighing why donors had more small for gestational age (SGA) births than matched nondonors, and whether shared genetics with recipients could play a role.¹

American Society of Nephrology (ASN) Kidney Week 2026

 by Amit X. Garg, MD, PhD, and published simultaneously in 

, spanned 3 provinces and also found a modest increase in hypertensive disorders of pregnancy among donors.¹

Interpreting Kidney Donor Pregnancy Signals, With Amit Garg, MD, PhD

How Did the Study Compare Donors and Nondonors?

Using linked administrative health databases from Ontario, British Columbia, and Alberta, investigators compared 385 pregnancies in 252 living kidney donors with 1,540 matched pregnancies in 1,535 nondonors.¹ To reflect donors’ healthier baseline profile, nondonors with any of 35 conditions that would preclude donation were excluded. Pregnancies were matched 1:4 on delivery date, maternal age, time from cohort entry to delivery, parity, and income.¹

The primary outcome, hospitalization with gestational hypertension, preeclampsia, or eclampsia, occurred in 11.9% of donor pregnancies vs 8.3% of nondonor pregnancies (risk ratio [RR], 1.51; 95% CI, 1.10-2.08).¹ More than 88% of donor pregnancies were unaffected, and rates of other outcomes, including severe maternal morbidity, preterm birth or low birth weight, and neonatal intensive care admission, were similar between groups.¹

Why Might Small for Gestational Age Births Have Been More Common in Donor Pregnancies?

Among 12 secondary outcomes, SGA birth, defined as birth weight below the 10th percentile, occurred in 13.8% of donor pregnancies vs 7.9% of nondonor pregnancies (RR, 1.86; 95% CI, 1.37-2.52).¹ In post hoc analyses, the association persisted at stricter thresholds, including birth weight below the fifth percentile (6.5% vs 3.6%) and the third percentile (4.7% vs 1.9%).¹

“One possibility is chance, particularly given the number of secondary outcomes we examined. At the same time, there is biological plausibility,” said Garg, professor of medicine, epidemiology and biostatistics at Western University, nephrologist at London Health Sciences Centre, and corresponding author of the study, in an interview with HCPLive.

Garg explained that reduced kidney function may impair normal renal adaptation to pregnancy and, in turn, may affect placental development and blood flow. In the paper, investigators cited an experimental model in which mice with 1 kidney removed showed impaired kidney adaptation to pregnancy, with abnormal placental development and placental hypoperfusion.¹ According to Garg, the finding warrants evaluation and confirmation in future studies.

Could Genetics Explain the Pregnancy Risks Seen in Kidney Donors?

Investigators flagged residual genetic confounding as a limitation. In Ontario, where donor-recipient relationship data were available, 63.9% of donors were first-degree relatives of their recipients.¹ Garg noted that few nondonors would be expected to have a first-degree relative with kidney failure, so inherited susceptibility could contribute to the observed association. Post hoc analyses, limited by small event counts, could neither confirm nor rule out a difference in risk by relatedness.¹

Garg pointed to several observations that reduce this concern. All donors had normal measures of kidney health at evaluation, and pregnancies occurred a mean of 5.6 years after donation.¹ By design, individuals with a recorded hypertensive disorder of pregnancy before cohort entry were excluded.¹ In Canada, individuals with these complications would generally not be accepted as donors while still of childbearing age, he added.

“So certainly, genetic confounding remains possible, but these observations make it less likely to fully explain the observed association,” Garg said.

Editor’s Note: Garg reported no relevant disclosures.

Wang C, Naylor KL, McArthur E, et al. Pregnancy outcomes after living kidney donation. 

. Published online October 22, 2026. doi:10.1001/jama.2026.21737

Garg AX. Pregnancy outcomes after living kidney donation. Presented at: American Society of Nephrology Kidney Week 2026; October 22, 2026; Denver, CO. Abstract TH-OR117.

Chance, biology, and shared genetics may explain more small for gestational age births after living kidney donation.

Future pregnancy plans need not rule out living kidney donation, but candidates should be counseled on hypertensive risk.

New data on pregnancy after living kidney donation give transplant teams clearer numbers to share with donor candidates who may want children in the future.¹

In a matched cohort study from 3 Canadian provinces, presented at 

, most donor pregnancies were uncomplicated, with a modest increase in hypertensive disorders of pregnancy.¹

Counseling Kidney Donors on Future Pregnancy, With Amit Garg, MD, PhD

Will Donating a Kidney Affect Future Pregnancies?

In 2024, more than 40,000 living kidney donations were reported across 88 countries.¹ For donors who may become pregnant later, Garg said the central question is whether donation will affect those pregnancies.

In the cohort of 385 donor pregnancies and 1,540 pregnancies in matched nondonors of similar baseline health, hospitalization with gestational hypertension, preeclampsia, or eclampsia occurred in 11.9% vs 8.3% (risk ratio [RR], 1.51; 95% CI, 1.10-2.08), and more than 88% of donor pregnancies were unaffected.¹ Small for gestational age births were also more common (13.8% vs 7.9%; RR, 1.86; 95% CI, 1.37-2.52), a secondary finding Garg said could reflect chance or biology. Rates of severe maternal morbidity, cesarean delivery, postpartum hemorrhage, gestational diabetes, preterm birth or low birth weight, and neonatal intensive care admission were similar between groups.¹

What Do the Findings Mean for Living Kidney Donation?

“If someone is interested in having a pregnancy after donation, that doesn’t preclude them from being a donor,” said Garg, professor of medicine, epidemiology and biostatistics at Western University, nephrologist at London Health Sciences Centre, and corresponding author of the study, in an interview with HCPLive.

Garg also emphasized encouraging healthy lifestyle behaviors after donation, noting obesity is associated with greater preeclampsia risk, along with appropriate monitoring for these complications. With living kidney donation performed worldwide, he said transplant centers should be confident donors will have access to good maternal care should they become pregnant.

How Should Clinicians Counsel Kidney Donor Candidates About Pregnancy?

The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) guideline on living kidney donors recommends counseling donor candidates about the potential for an increased risk of gestational hypertension or preeclampsia.² According to Garg, the findings support this guidance, including asking candidates about future pregnancy plans during evaluation.

Age may matter in these conversations. In subgroup analyses, the RR for the primary outcome was larger among pregnancies at a maternal age of 35 years or older (14.3% vs 7.6%; RR, 1.99; 95% CI, 1.18-3.33) than among younger mothers (RR, 1.41; 95% CI, 0.93-2.15).¹

“When we counsel donor candidates, we should discuss the possible effect of donation on future pregnancy, including a higher risk of gestational hypertension or preeclampsia,” Garg said.

Investigators noted that most Canadian donors are White and receive care in publicly funded health systems, which may limit generalizability, and called for additional study among donors of African ancestry, including those with apolipoprotein L1 high-risk genotypes.¹

Lentine KL, Kasiske BL, Levey AS, et al. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. 

. 2017;101(8S suppl 1):S1-S109. doi:10.1097/TP.0000000000001769

Future pregnancy plans don’t preclude living kidney donation, but candidates should be counseled on gestational hypertension risk.

A Canadian cohort found modestly greater preeclampsia risk after donation, though most pregnancies were uncomplicated.

Is Pregnancy Riskier for Living Kidney Donors? With Amit X. Garg, MD, PhD

Phoom Narongkiatikhun, MD, is affiliated with the University of Washington School of Medicine and Chiang Mai University.

Phoom Narongkiatikhun, MD, discusses sleeve gastrectomy reducing LV mass, kidney volume, and albuminuria and boosting medullary FSOC in youth-onset T2D. 

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D

Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy

Christoph Correll, MD, is a clinical professor of psychiatry at the Zucker School of Medicine at Hofstra/Northwell.

Christoph Correll, MD, discusses how once-monthly subcutaneous olanzapine fills an LAI gap and why continuous coverage matters in schizophrenia.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Once-Monthly Olanzapine for Schizophrenia, With Christoph Correll, MD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her various hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Participants described how payer requirements and documentation of steroid exposure shape biologic access.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Experts Examine Biologic Coverage in Asthma and COPD

In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.

FDA News

Ravulizumab Receives FDA Accelerated Approval for IgA Nephropathy

An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.

Lack of CKD Awareness Limits GLP-1 RA Kidney Protection in Over 9 Million US Adults

Sandra L. Kane-Gill, PharmD, MS, is a professor of pharmacy and therapeutics and associate dean of faculty affairs at the University of Pittsburgh School of Pharmacy. 

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

Latest News

Lorundrostat Lowers BP, Albuminuria in CKD With Uncontrolled Hypertension

What’s New in Nonsurgical Skin Cancer Care, With Todd Schlesinger, MD

Edoxaban Fails to Improve Stroke Risk, Increases Bleeding Risk After Intracranial Hemorrhage

Interpreting Kidney Donor Pregnancy Signals, With Amit Garg, MD, PhD

Counseling Kidney Donors on Future Pregnancy, With Amit Garg, MD, PhD